Answers are grounded in this paper and cite their sources.
Dupilumab + TCS is efficacious and well tolerated in children with severe AD, significantly improving signs, symptoms, and QOL.
No takes yet. Share an insight, caveat, or question.
Paller et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: